A Randomized, Open-label, Phase Ib/IIa Clinical Study to Evaluate the Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors, Including Advanced Well Differentiated/Dedifferentiated Liposarcoma.
Latest Information Update: 24 Oct 2023
At a glance
- Drugs Cadonilimab (Primary) ; I 022 (Primary)
- Indications Liposarcoma; Solid tumours
- Focus Therapeutic Use
- Sponsors Shanghai Pharmaceuticals Holding
Most Recent Events
- 17 Oct 2023 Status changed from not yet recruiting to recruiting.
- 17 Jul 2023 New trial record